All the completed or ongoing clinical trials investigating MPS1 inhibitors have been performed on patients with advanced malignancies (solid tumors) or breast cancer, with no reference to treatments in patients with oral or head and neck cancer. The gene discussed is TTK; the disease is breast carcinoma.